Search
Mandelic acid
go.drugbank.com/drugs/DB13218ApprovedMandelic acid is an approved aromatic, alpha hydroxy acid [L5458]. Mandelic acid is used as an ingredient in cosmetics and drug products applied topically.
Rintodestrant
go.drugbank.com/drugs/DB21472InvestigationalRintodestrant is under investigation in clinical trial NCT03455270 (G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast Cancer). … Rintodestrant is a small molecule drug.
Selpercatinib
go.drugbank.com/drugs/DB15685ApprovedInvestigational[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. … [A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific
Categories: MATE 1 Inhibitors, P-glycoprotein inhibitorsSynonyms: 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrileCusatuzumab
go.drugbank.com/drugs/DB15100InvestigationalAn overexpression of CD70 can result in the proliferation of malignant cells and has been documented in a variety of solid and hematological malignancies. … CD70 is a ligand expressed on the surface of activated lymphocytes and mature dendritic cells that, in its binding to CD27 receptors, plays an important role in cell proliferation and survival.
Ledipasvir
go.drugbank.com/drugs/DB09027ApprovedThis is an important advantage relative to HCV drugs that target other viral enzymes such as the protease, for which rapid development of resistance has proven to be an important cause of therapeutic failure … Ledipasvir is a direct acting antiviral (DAA) medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV).
Mixtures: HARVONI®Categories: P-glycoprotein inhibitors, P-glycoprotein substratesZanubrutinib
go.drugbank.com/drugs/DB15035ApprovedInvestigational[A187967] BTK is an enzyme that plays a role in oncogenic signalling pathways, promoting the survival and proliferation of malignant B cells. … [L10163] Mantle cell lymphoma is an aggressive mature B-cell non-Hodgkin lymphoma associated with early relapse, poor clinical outcomes, and long-term survival.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2B6 Substrates with a Narrow Therapeutic IndexLunsotogene parvec
go.drugbank.com/drugs/DB18278ApprovedInvestigationalLunsotogene parvec is a first-in-class dual adeno-associated virus serotype 1 vector-based gene therapy developed to address an unmet medical need for OTOF-related sensorineural hearing loss. … [L56137] It acts by delivering functional copies of the human _OTOF_ gene specifically to inner hair cells via an engineered hair-cell-specific Myo15 promoter, which restores essential synaptic transmission
Durlobactam
go.drugbank.com/drugs/DB16704ApprovedInvestigational[L47336] The combination product of durlobactam and sulbactam was first approved by the FDA in May 2023. … Durlobactam is a diazabicyclooctane non-beta-lactam, beta-lactamase inhibitor. It is typically given in combination with [sulbactam] to protect it from degradation by certain serine-beta-lactamases.
Synonyms: (2S,5R)-2-CARBAMOYL-3-METHYL-7-OXO-1,6-DIAZABICYCLO(3.2.1)OCT-3-EN-6-YL SULFATE, SULFURIC ACID, MONO((2S,5R)-2-(AMINOCARBONYL)-3-METHYL-7-OXO-1,6-DIAZABICYCLO(3.2.1)OCT-3-EN-6-YL) ESTERDermatophagoides pteronyssinus
go.drugbank.com/drugs/DB10401ApprovedInvestigationalThis combination is approved for as a year-round, once-a-day tablet that's dissolved under the tongue as a treatment for dust mite allergies.
Mixtures: SLITone ULTRA D. pteronyssinus/ D. farinae, Standardized Mite Mix, Dermatophagoides pteronyssinus and Dermatophagoides farinae, 10000 AU per mLProducts: Standardized Mite D Pteronyssinus, Standardized Mite D. pteronyssinus